{"nctId":"NCT00595790","briefTitle":"Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51","startDateStruct":{"date":"2005-09"},"conditions":["Japanese Encephalitis"],"count":374,"armGroups":[{"label":"IC51 2 x 6 mcg","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: IC51"]},{"label":"IC51 1 x 12 mcg","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: IC51"]},{"label":"IC51 1 x 6 mcg","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: IC51"]}],"interventions":[{"name":"IC51","otherNames":["Japanese Encephalitis purified inactivated vaccine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* At least 18 years of age\n* Written informed consent obtained prior to study entry\n\nExclusion Criteria:\n\n* History of clinical manifestation of any flavivirus infection\n* History of vaccination against Japanese encephalitis (JE), Yellow fever and Dengue fever (an anti-JEV neutralizing antibody titer \\>= 1:10 at baseline is acceptable for inclusion, these subjects will be part of the safety population, but will not be analyzed for immunogenicity in the per-protocol analysis)\n* Use of any other investigational or non-registered drug or vaccine in addition to the study vaccine during the study period or within 30 days preceding the first dose of study vaccine\n* Immunodeficiency including post-organ-transplantation or immunosuppressive therapy\n* A family history of congenital or hereditary immunodeficiency\n* History of autoimmune disease\n* Any acute infections within 4 weeks prior to enrollment\n* Infection with HIV, Hepatitis B or Hepatitis C\n* Pregnancy, lactation or unreliable contraception in female subjects","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"SCR (Seroconversion Rate) at Day 56","description":"Seroconversion rate: percentage of subjects with \\>= 1:10 anti-JEV neutralizing antibody titer","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.2","spread":null},{"groupId":"OG001","value":"97.3","spread":null},{"groupId":"OG002","value":"25.6","spread":null}]}]}]},{"type":"SECONDARY","title":"SCR at Day 10, 28 and 35","description":null,"classes":[]},{"type":"SECONDARY","title":"GMT at Day 10, 28, 35 and 56","description":null,"classes":[]},{"type":"SECONDARY","title":"Safety","description":"AEs, Local and systemic tolerability, Safety laboratory parameters","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":125},"commonTop":["Myalgia","Headache","Influenza like illness","Fatique","Pharyngolaryngeal pain"]}}}